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to IABP.
CONCLUSIONS This is the largest and the most contemporary study
on the use of hemodynamic support which demonstrates signiﬁcantly
reduced mortality and complications with PVADs when compared to
IABP in patients undergoing PCI and this effect is largely driven by the
improved outcomes in non-AMI and non-cardiogenic shock patients.
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BACKGROUND Impella (Abiomed Inc, Danvers, Mass) is a percuta-
neous left ventricular assist device used in the setting of high-risk
coronary intervention, cardiogenic shock and ablation procedures.
METHODS This is a single center study evaluating the use of Impella
in high-risk patients undergoing PCI. Impella use was classiﬁed as
‘elective’ in patients who were identiﬁed to be high-risk or in shock
prior to the procedure (Group 1, N¼ 129). Patients who received an
Impella as a result of an acute hemodynamic compromise or proce-
dural complication were classiﬁed as ‘emergent’ (Group 2, N¼ 57). The
primary endpoint was a composite MACE of in hospital mortality;
vascular complications and BARC deﬁned bleeding.
RESULTS Between 2010 and 2014, 187 high-risk patients underwent
Impella placement. The baseline demographics of both groups were
similar (Fig 1). The mean age was 67.5 years (p¼ns). The mean ejection
fraction was 28.3% (p¼ns). Elective Impella use (group 1) was
associated with more complete revascularization (2.3 vs 1.3 stents,
p<0.001), successful weaning and explant of Impella at end of
procedure (79% vs 10%, p<0.001) and successful hemostasis with
perclose in preclose fashion (81% vs 8%, p<0.001). The MACE rate
in Group 1 was 24% v/s 67% in Group 2 (p<0.001) (Table 1). The
drivers of this difference in MACE were in-hospital mortality (9% v/s
49%; p<0.001) and need for more blood transfusions in the
emergent group (1.3% v/s 2.9;p¼0.009). In multivariate analysis,
independent predictors of in hospital MACE events were emergent
Impella placement (OR 6.14, p<0.001), baseline ejection fraction and
removal of Impella at the end of the procedure (Fig 1).Outcomes Elective Emergent p-valueMACE 24 % (32) 67 % (41) <0.001Any Bleeding 23 % (30) 34 % (21) 0.09BARC major or life
threatening
bleeding15 % (19) 31 % (19) 0.48In-hospital death 9 % (12) 49 % (30) <0.001Vascular
Complications15 % (20) 16 % (10) 0.84Units of PRBCs infused 1.3  3.7 2.9  4.6 0.009
Bleeding at implant
site8 % (11) 15 % (9) 0.18Duration of procedure
(minutes  SD)
143  60 113  48 0.001Median length of stay
(Days  SD)
6  9.2 5  11 0.88CONCLUSIONS The real world use of the Impella mimics use in the
PROTECT 2 trial with similar baseline demographics and ejection
fraction. The elective use is largely in the setting of HRPCI whereas
the emergent use is largely in the setting of cardiogenic shock. In
hospital mortality and MACE in the emergent setting remain very high
whereas in the elective setting especially with early device explant,
the in-hospital mortality and MACE rates are low.
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BACKGROUND IABP is a widely used circulatory support device. The
IABP-SHOCK II trial (2012) showed that IABP did not improve 30-day
mortality. US and European guidelines have subsequently revised
their recommendations for IABP from class I to IIa and IIb, respec-
tively. Despite limited evidence, peripheral VA-ECMO is an estab-
lished treatment for refractory cardiogenic shock (CS). Current
guidelines have a IIb recommendation for use. The aim of this retro-
spective, observational analysis was to study the contemporary usage
patterns and outcomes of IABP, as well as to understand our early
experience with VA-ECMO in patients who have initially received an
IABP, at a single center.
METHODS From January 2010 to September 2014, we retrospec-
tively analyzed the Cardiac Catheterization database at Liverpool
Hospital, Sydney, for consecutive patients receiving an IABP,
including those who subsequently required VA-ECMO during the
same admission.
RESULTS Among 219 patients, who received a total of 222 IABP in-
sertions (mean age 65.911.8 years, range 23.1-91.4 years), 49 (22%)
were women; 38 (17%) had diabetes mellitus; 35 (16%) had left main
stenosis >70%; 29 (13%) were administered a GPIIbIIIa antagonist; 60
(27.4%) died during hospitalization. The 7.5Fr 40cc Sensation cath-
eter (Maquet, USA) was most commonly utilized (146 cases, 65.7%).
Mean dwell time was 46.143.7 hours (range 0.3–240 hours). Com-
plications occurred in 9 cases (2 severe access site bleeding requiring
transfusion, 1 minor access site bleeding, 4 leg ischemia, 1 access
related sepsis,1 IABP related mortality). CS was the commonest
indication and had high in-hospital mortality (46.3%). A total of 7
patients required VA-ECMO (mean age 64.79.6 years, range 49 to
75.2 years), 2 were women; 4 had diabetes mellitus. VA-ECMO was
initiated before left main stenting in 2 cases, and after revasculari-
zation in the others. IABP was left in situ in 3 patients. VA-ECMO was
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time from decision to cannulation was 43 hrs (range 2-10 hours).
The average duration of VA-ECMO was 6.165.5 days (range 3 hours
to 14 days). Access related complication occurred in 2 cases (1 major
bleeding, 1 leg ischemia). Death occurred in 71.4% (5 patients).Indications and Outcomes of IABP
INDICATIONS TOTAL n(%) 2010 2011 2012 2013 2014@
MORTALITY
n(%)#
Post myocardial
infarction (MI)
cardiogenic shock
95 (42.8%) 14 17 21 23 20 44 (46%)
Pre-operative support
for cardiac surgery
75 (33.8%) 18 14 17 20 6 5 (6.7%)
High risk/complicated
angioplasty/
catheterization*
41 (18.4%) 10 9 5 11 6 7 (17%)
Complications of MI
ˇ
4 (1.8%) 1 0 2 1 0 3 (75%)
Refractory post MI
angina
4 (1.8%) 2 1 0 1 0 1 (25%)
Refractory left
ventricular failure
2 (0.9%) 1 0 1 0 0 0
Refractory ventricular
arrhythmias
1 (0.5%) 0 0 0 1 0 0
222 (100%) 46 41 46 57 32 60 (27.4%)
*left main stenting, dissections, STEMI without CS, severe triple vessel disease,
ˇ
ventricular septal defect,
papillary muscle rupture, #in hospital all-cause mortality, @9 months data only.CONCLUSIONS In our experience, IABP was most commonly utilized
in CS complicating myocardial infarction. The trend of use for this
indication does not seem to have reduced after IABP-SHOCK II. Over
half of the IABPs inserted were for indications other than CS. VA-
ECMO may be life-saving treatment after failure of IABP support in
shocked patients. Appropriate patient selection for VA-ECMO is
challenging. Clinical trial of IABP may aid patient triage
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BACKGROUND Percutaneous cardiopulmonary support (PCPS) is a
widely accepted treatment for severe cardiopulmonary failure
because this system can be rapidly applied in emergency situations.
However, there is no available data on clinical outcome in patients
between cardiac and non-cardiac origin cardiopulmonary failure.
METHODS We analyzed 61 consecutive patients with severe cardio-
pulmonary failure and complicating cardiogenic shock who were
assisted by an emergent bypass system (EBSTerumo, Tokyo, Japan)
between January 2012 and May 2015. The primary outcome was the
success rate of weaning from EBS. The secondary outcome was in-
hospital mortality.
RESULTS The mean duration of PCPS was 77.6 hours and that of car-
diopulmonary resuscitation (CPR) was 32 (52.5%). The rate of weaning
was 23 (37.7%) and the rate of weaning from cardiac group was higher
than non-cardiac group (51.2% vs. 10.0%, p¼0.002). In-hospital mor-
tality occurred for 45 patients (63.4% vs. 95.0%, p¼0.012).Table 1. Univariate analysis between cardiac and non-cardiac groupCardiac (n[41) Non-cardiac (n[20) p-valueAge (years) 63.7  12.4 54.8  15.0 0.017
Sex, male (%) 29 (70.7) 14 (70.0) 1.000BMI (Kg/m2) 23.5  3.7 23.6  4.0 0.965
APACHEII score 16.2  9.8 21.8  12.7 0.068
Mean BP (mmHg) 78.0  13.5 79.6  25.6 0.754
Ejection Fraction (%) 40.4  16.8 51.6  13.5 0.017
Estimated GFR 49.5  33.8 39.7  23.5 0.271
Troponin I (ng/mL) 33.9  51.4 9.4  35.1 0.071
CRRT (%) 16 (39.0) 14 (70.0) 0.031Vasopressor (%) 41 (100) 18 (90.0) 0.104CPR (%) 18 (43.9) 14 (70.0) 0.064Weaning (%) 21 (51.2) 2 (10.0) 0.002ECMO time (hours) 79.5  14.1 67.9  19.9 0.641CONCLUSIONS Cardiopulmonary failure with non-cardiac origin was
associated with high mortality. An APACHE II score & renal replace-
ment therapy might serve as outcome for risk stratiﬁcation.
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BACKGROUND No studies have explored hemodynamic variables
associated with right ventricular dysfunction (RVD) in the The SHould
we emergently revascularize Occluded coronaries for Cardiogenic
shock (SHOCK) trial and registry including: central venous pressure
(CVP), CVP/pulmonary capillary wedge pressure (PCWP) ratio, pul-
monary artery pulsatility index (PAPi), and right ventricular stroke
work index(RVSWI). The Recover Right Trial deﬁned RV failure using
three variables (RR-RVF Criteria) including a cardiac index < 2.2, CVP
> 15 or CVP/PCWP>0.63, or use of an inotrope or vasopressor. We
explored the hypothesis that RVD is common and contributes to
higher mortality in the setting of acute myocardial infarction
complicated by cariogenic shock (AMI-CS).
